Atlas FDA

Amplatzer™ Talisman™ PFO Occluder

FDA premarket approval P120021/S020 · decided 2021-09-27

Approval details

PMA number
P120021
Supplement
S020
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
Amplatzer™ Talisman™ PFO Occluder
Generic name
Transcatheter septal occluder
Applicant
ABBOTT MEDICAL
Date received
2021-04-01
Decision date
2021-09-27
Days to decision
179 days
Decision code
APPR
Product code
MLV
Advisory committee
Cardiovascular
Expedited review
No
Location
St. Paul, MN
Statement
Approval for the Amplatzer Talisman PFO Occluder (Talisman PFO); a line extension of the current Amplatzer PFO Occluder (PFO) product family.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
EnSite™ X EP System (K262006)Abbott Medical2026-07-15
Amplatzer TorqVue Exchange System (K261631)Abbott Medical2026-06-17
OPTIS Mobile Next Imaging System (1014932); OPTIS Integrated Next Imaging System (1014933); Ultreon 3.0 Software Upgrade Kit (ULTR300001) (K253459)ABBOTT MEDICAL2026-04-24
EnSite™ X EP System (K260212)ABBOTT MEDICAL2026-04-20
Disposable Radiofrequency Cannula (K253907)ABBOTT MEDICAL2026-04-16
Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80 (K260499)ABBOTT MEDICAL2026-03-13
Armada™ 14 NC PTA Catheter (K252512)ABBOTT MEDICAL2026-02-13
Assert-IQ (DM5100) (K253516)ABBOTT MEDICAL2025-12-18